Business Context and Reporting Period
Company: Biomerica, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended August 31, 2009 (First Quarter of Fiscal 2010)
Business Overview: Biomerica manufactures and markets diagnostic products for clinical laboratories. The company is classified as a smaller reporting company and trades on the OTC-Bulletin Board.
Key Financial Metrics
| Metric | Q1 2010 (Ended Aug 31, 2009) | Q1 2009 (Ended Aug 31, 2008) |
|---|---|---|
| Net Sales | $1,148,521 | $1,194,345 |
| Gross Profit | $376,437 | $533,129 |
| Gross Margin | 32.8% | 44.6% |
| Operating Income | $4,719 | $147,258 |
| Net Income | $7,934 | $140,812 |
| Diluted EPS | $0.00 | $0.02 |
| Cash and Equivalents | $1,692,165 | $1,960,826 (End of Period) |
| Working Capital | $3,802,237 | $3,831,112 (May 31, 2009) |
| Debt (Equipment Loan) | $112,511 | $122,781 (May 31, 2009) |
Cash Flow Summary: Net cash provided by operating activities was $31,870. Investing activities provided $75,086 (primarily due to the maturity of a $100,000 short-term investment). Financing activities used $10,270 (primarily equipment loan payments).
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased by 3.8% ($45,824) compared to the prior year quarter. Management attributes this primarily to a decrease in clinical laboratory sales due to the timing of orders.
- Margin Compression: Gross margin declined significantly from 44.6% to 32.8%. Cost of sales as a percentage of sales increased by 11.8% due to higher capitalization of labor and overhead, increased CE Mark expenses, outside services, wages, and repairs.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses decreased by 16.3% ($55,446) due to reduced accounting, commissions, and wages. Conversely, Research and Development (R&D) expenses increased by 87.8% ($41,293) driven by increased personnel and new product research.
- Profitability: Net income dropped sharply to $7,934 from $140,812 in the prior year, reflecting the margin compression and increased R&D spend.
Outlook, Risks, and Unusual Items
- Facility Relocation: In September 2009, the company began moving to a new facility. Management anticipates the majority of personnel and assets will be operational at the new location by early November 2009. Unforeseen difficulties in this move are cited as a risk factor.
- Liquidity and Credit: The company maintains a $400,000 line of credit with Union Bank of California, which had a zero balance as of August 31, 2009. An equipment loan of $133,000 (6.50% interest) was entered into in February 2009 to refinance a prior loan.
- Risk Factors: Key risks include macroeconomic downturns, diminished access to raw materials, shipping disruptions, inability to control margins due to competition, regulatory delays, and potential litigation regarding product harm.
- Forward-Looking Statements: Management cautions that anticipated future revenues and product success involve significant uncertainties and may differ materially from actual results.
Investor Verification Checklist
- Margin Sustainability: Verify if the 11.8% increase in cost of sales is a one-time anomaly or a structural shift affecting future profitability.
- Revenue Timing: Assess whether the decline in clinical laboratory sales is purely due to order timing or indicative of weakening demand.
- R&D ROI: Monitor the impact of the 87.8% increase in R&D spending on future product launches and revenue growth.
- Facility Move: Confirm the completion of the facility relocation by November 2009 and check for any operational disruptions or cost overruns.
- Inventory Levels: Review inventory reserves and obsolescence risks, particularly given the company's reliance on forecasting customer demand for new products.